The efficacy of prazosin for the treatment of posttraumatic stress disorder nightmares in U.S. military veterans.
Annamarie Breen, Kory Blankley, Julie Fine
Journal of the American Association of Nurse Practitioners December 15, 2016 DOI: 10.1002/2327-6924.12432 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Population | U.S. military veterans with posttraumatic stress disorder and trauma-related nightmares |
| Intervention | Prazosin |
| Dose | initiated at 1 mg, titrated upward; maximum 20 mg at bedtime and 5 mg midmorning |
| Topics | Dreaming PTSD |
| Keywords | Humans Prazosin Treatment outcome Dreams Sleep Stress disorders, post-traumatic Veterans United states Nightmares |
| Key findings | The authors conclude that prazosin is effective for PTSD trauma-related nightmares and, given its low side-effect profile and benefits for sleep, recommend it as an adjunctive treatment. They advise starting at 1 mg and titrating to effect, up to 20 mg at bedtime and 5 mg midmorning. |
Abstract
Background and
Purpose: Nightmares associated with posttraumatic stress disorder (PTSD) are a hallmark symptom among U.S. military veterans who have seen combat. Management of combat-related nightmares can be difficult and current pharmacologic options are limited and tend to have adverse side effects. The aim of this review is to explore recent literature regarding the efficacy of prazosin for the treatment of nightmare disorder in the veteran population.
Methods: Recent literature consisting of three systematic reviews was reviewed, as well as current clinical guidelines published by The Department of Veterans Affairs (VA) and The Department of Defense (DoD) and the American Academy of Sleep Medicine (AASM).
Conclusions: Prazosin has been shown to be effective in the treatment of PTSD trauma-related nightmares. As a result of its low side effect profile and abilities to improve both sleep and reduce trauma nightmares, prazosin has been recommended as an adjunct therapy. Implications for practice: Prazosin should be initiated as an adjunctive treatment to promote sleep in those suffering from PTSD nightmares. It should be initiated at 1 mg and then titrated upward until absence or desired reduction of nightmares is achieved, with a maximum dosage recommendation of 20 mg at bedtime and 5 mg midmorning.
Comparable studies
Other narrative reviews on PTSD, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Psychedelic Psychiatry's Brave New World. | 2020 | Review | |
| Reviewing the Potential of Psychedelics for the Treatment of PTSD | 2020 | Review | |
| Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA. | 2016 | Review | |
| MDMA-assisted psychotherapy for PTSD: Are memory reconsolidation and fear extinction underlying mechanisms? | 2018 | Review | |
| Clinical applications of hallucinogens: A review. | 2016 | Review |
Citations in the library
Cites 3
- Pharmacological and non-pharmacological treatments for nightmare disorder. International Review of Psychiatry April 1, 2014
- Replication and expansion of "Best Practice Guide for the Treatment of Nightmare Disorder in Adults". Journal of Clinical Sleep Medicine October 1, 2011
- Best practice guide for the treatment of nightmare disorder in adults. Journal of Clinical Sleep Medicine August 1, 2010